Genmab — Juni 2016
-
-
Ohad har et skriv om ASCO med en Dara sales graf:http://www.orf-blog.com/notes-from-asco-2016/
-
Meget konservativ. Den skal fordobles. Med hans estimat har vi ikke meget potentiale tilbage
-
Salgsestimatet skal fordobles!
-
Han har 657m for 2017. Det når vi nok i år!
-
Estimatet er kun for USA. Så er han mere inline med andre estimater
-
Tak for Update bongobob. Det ligner et generelt skuffende asco i år - som sektor er det nok ikke de bedste nyheder for biotek, men for GENs pipeline drømme er det jo lige i skabet!
-
Når der kommer lidt mere kød på Gens pipeline - specifikation af targets og mulige indikationer - kunne det være interessant at lave et bibliotek over eksisterende backbone behandlinger og deres effekt, og måske også relevante terapier under udvikling. Nogen interesserede?
-
JnJs CFO Dominic Caruso said yesterday at the Goldman Healthcare conference, that JnJ expects to see a multiple myeloma market around USD 14-15bn already in 2020 (from 8-9bn today) and that Darzalex should have the lions share of that market
-
Fantastikt
-
Dr. Jesus San Miguel noted that when POLLUX data mature, the median progression free survival (PFS) will likely reach a whopping 40 months or more than 3 years.
-
Endnu bedre
-
It could even be median PFS of 50 months
-
De foregående quotes er fra Novod der igår har deltaget I et pre EHA symposium
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind